IGC Pharma's Preclinical Data for IGC-1C
IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
POTOMAC, MD -- October 7, a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced in-vitro findings for IGC-1C, a low-molecular weight compound. The data are consistent with IGC-1C acting as a modulator of the tau protein's liquid-liquid phase separation (LLPS), an emerging and critical pathway implicated in the earliest stages of Alzheimer's disease and related tauopathies.
IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed.
The LLPS pathway represents a potential paradigm shift in neurodegenerative research. When dysregulated, tau protein separates into liquid-like droplets, or condensates, which serve as the pathological "seeds" that mature into neurotoxic fibrillar aggregates (neurofibrillary tangles). By targeting the initial LLPS stage, IGC-1C offers the potential to halt the disease progression before irreversible damage occurs, a therapeutic approach distinct from late-stage plaque or tangle inhibitors.
"IGC-1C can potentially target a key and early pathological event in Alzheimer's disease. By intervening at the phase separation stage, we aim to prevent the formation of toxic tau aggregates, opening a novel and potentially scalable pathway to halt disease progression. This is a disruptive therapeutic concept that has the potential to redefine the treatment landscape for Alzheimer's and other tauopathies." Said, Ram Mukunda, CEO of IGC Pharma.
Preclinical experimental findings suggest IGC-1C's mechanism of action and demonstrate powerful efficacy markers.
About IGC Pharma
IGC Pharma is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With more than 30 patent filings, 12 patents granted and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
